Martinsried/Munich, Germany, February 21, 2008 - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Astellas Pharma Inc., Japan’s second largest ethical pharmaceutical company, has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term. Under the agreement, which is now extended for four more years until March 2012, Astellas will continue to have access to MorphoSys’s proprietary antibody library HuCAL GOLD at its research site in Tsukuba, Japan. Furthermore, the extension includes an option for Astellas to develop and commercialize HuCAL-derived therapeutic antibodies, in which case MorphoSys would receive exclusive license fees and milestone payments, as well as royalties. Under the extended agreement MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.
“We are very pleased by the successful progress in our collaboration with Astellas and their decision to continue using our HuCAL GOLD technology for their antibody development programs,” commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. “Today’s news is a clear signal that our HuCAL technology will continue to be the basis of drug development programs at a number of companies throughout the global pharmaceutical industry.”
About MorphoSys: MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys’s goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 40 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL(R) and HuCAL GOLD(R) are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
